This text is a result of machine translation.
Commentary of financial Associated Press: the framework agreement should also be made clear that the letter Phi cannot ambush
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Yesterday 12:13 PM
Changes in the aquaculture sector pulled Fucheng shares up by the daily limit
Oil and gas stocks fell at the opening, and many stocks fell by more than 5%
Accelerated shuffle of pig breeding leaders with uneven fat and lean
Nonferrous metal plate strengthened due to shock, and changal shares rose by the limit
Zhengbang technology responded to the overdue non cashing of 500million commercial bills: the company is actively negotiating and communicating with creditors
360 DigiTech: A Leader in an Oscillating Market
360 DigiTech's core competencies of asset-light model and technology focus offer a bright future. In the first quarter of 2022, the firm outperformed its competitors in terms of user amount, total loans granted and revenue. However, it operates in a market that has been performing below expectations as risks mount and profitability decreases.
Updated 2 hours ago
Zhengbang Technology: the total amount of equity assets of some feed holding subsidiaries sold to Dabei agriculture is about 2-2.5 billion yuan
Guotai Junan: the improvement of pig cycle reversal is expected to continue to accelerate